<DOC>
	<DOCNO>NCT00392886</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . A bone marrow peripheral stem cell transplant use stem cell patient may able replace blood-forming cell destroy chemotherapy . This may allow chemotherapy give tumor cell kill . PURPOSE : This phase III trial study well give combination chemotherapy without etoposide follow autologous stem cell transplant work treat young patient previously untreated malignant brain tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Etoposide Followed By Autologous Stem Cell Transplant Treating Young Patients With Previously Untreated Malignant Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year event-free survival ( EFS ) overall survival ( OS ) pediatric patient previously untreated nondisseminated medulloblastoma ( &lt; 4 year age ) , disseminate medulloblastoma ( &lt; 10 year age ) , noncerebellar primitive neuroectodermal tumor ( PNET ) ( disseminate non-disseminated ) treat induction chemotherapy follow consolidation myeloablative chemotherapy autologous hematopoietic stem cell rescue . - Determine toxicity regimen patient . - Determine mortality patient treat regimen . Secondary - Determine complete partial response rate completion induction chemotherapy patient stratify accord pathology ( medulloblastoma v noncerebellar PNET v high-grade glioma vs atypical teratoid/rhabdoid tumor vs choroid plexus carcinoma atypical papilloma v ependymomas ) . - Describe EFS OS patient stratify accord additional diagnosis ( atypical teratoid/rhabdoid tumor vs choroid plexus carcinoma atypical choroid plexus papilloma v ependymomas vs high-grade glioma ) . - Describe time progression pattern relapse patient stratify diagnosis radiotherapy receive ( &lt; 6 year age evidence residual tumor pre-transplant post-transplant consolidation radiotherapy v &lt; 6 year age residual tumor present pre-transplant treat post-transplant consolidation radiotherapy v &gt; 6 year age treat post-transplant consolidation radiotherapy ) . - Determine neuropsychometric function , endocrinologic function , physical growth patient stratify accord radiotherapy receive ( none v reduced-volume craniospinal radiotherapy v focus local-field radiotherapy ) . OUTLINE : This pilot study . Patients stratify accord type tumor ( nonglial v glial diffuse pontine ) . - Regimen C ( patient glial tumor ) : - Stem cell harvesting ( bone marrow and/or peripheral blood ) : Patients undergo leukapheresis bone marrow aspiration collect bone marrow peripheral blood stem cell prior begin induction chemotherapy first course induction chemotherapy . - Induction chemotherapy : Patients receive vincristine IV day 1 , 8 , 15 course 1-3 , oral temozolomide daily day 1-5 , carboplatin IV 4 hour day 1 2 . Patients also receive G-CSF SC begin day 6 continue blood count recover . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients unresectable bulky disease corticosteroid dependence remove study . All patient proceed consolidation chemotherapy . - Consolidation chemotherapy : Patients receive carboplatin IV 4 hour day -8 -6 thiotepa IV 3 hour day -5 -3 . - Autologous bone marrow peripheral blood stem cell transplantation : Patients undergo reinfusion bone marrow peripheral blood stem cell day 0 . Patients also receive G-CSF SC begin day 1 continue blood count recover . - Radiotherapy : Beginning within 6 week stem cell transplantation , patient &gt; 6 year age diagnosis undergo radiotherapy daily 5 day week 4-6 week absence disease progression unacceptable toxicity . Patients ≤ 6 year age undergo radiotherapy evidence tumor remain completion induction chemotherapy . - Regimen D2 ( patient nonglial tumor ) : - Stem cell harvesting ( bone marrow and/or peripheral blood ) : Patients undergo leukapheresis bone marrow aspiration collect bone marrow peripheral blood stem cell prior begin induction chemotherapy first course induction chemotherapy . - Induction chemotherapy : - Courses 1 , 3 , 5 ( 28 day per course ) : Patients receive cisplatin IV 6 hour day 1 , cyclophosphamide IV 1 hour etoposide IV 2 hour day 2 3 , high-dose methotrexate IV 4 hour day 4 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 5 continue blood count recover . Patients also receive vincristine IV day 1 , 8 , 15 course 1 3 . - Courses 2 4 ( 28 day per course ) : Patients receive oral temozolomide daily day 1-5 , oral etoposide daily day 1-10 , cyclophosphamide IV 1 hour day 11 12 , G-CSF SC begin day 13 continue blood count recover . Patients also receive vincristine IV day 1 , 8 , 15 course 2 . Patients unresectable bulky disease corticosteroid dependence remove study . All patient proceed consolidation chemotherapy . - Consolidation chemotherapy : Patients receive carboplatin IV 4 hour day -8 -6 thiotepa IV 3 hour etoposide IV 3 hour day -5 -3 . - Autologous bone marrow peripheral blood stem cell transplantation : Patients undergo re-infusion bone marrow peripheral blood stem cell day 0 . Patients also receive G-CSF SC begin day 1 continue blood count recover . - Radiotherapy : Patients undergo radiotherapy regimen C. Patients regimens undergo neuropsychological test induction chemotherapy consolidation chemotherapy 18 , 36 , 54 month completion study treatment . Neuropsychometric neuroendocrine testing perform radiotherapy . Quality life also assess periodically . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant brain tumor , include follow : Posterior fossa medulloblastoma/primitive neuroectodermal tumor ( PNET ) * All stage allow Must &lt; 4 year age diagnosis unless evidence postoperative residual tumor ( &gt; 1.5 cm² tumor area ) evidence neuraxis extraneural dissemination ( highstage ) Medulloblastoma , cerebral neuroblastoma , ependymoblastoma allow Lowstage ( standardrisk ) medulloblastoma allow patient &gt; 4 year age Ependymoma* All stag location allow Cellular anaplastic subtypes allow ( myxopapillary ependymomas spinal cord ) Must &lt; 36 month age diagnosis posterior fossa tumor OR &lt; 72 month age supratentorial tumor Evidence neuraxis dissemination irrespective primary site No cellular ( lowgrade ) supratentorial ependymomas age complete resection parenchymally base ( i.e. , periventricular ) supratentorial tumor Brain stem tumor* All stage allow irrespective extent resection No unbiopsied diffuse intrinsic pontine tumor Tumor pathologically confirm either malignant glioma PNET allow Highgrade glioma** Primary atypical teratoid/rhabdoid tumor CNS* Choroid plexus carcinoma atypical choroid plexus papilloma* All stag location allow Anaplastic astrocytoma** Glioblastoma multiforme** Anaplastic oligodendroglioma** Anaplastic ganglioglioma** Other anaplastic mixed gliomas** Smallcell glioblastoma** Giantcell glioblastoma** Gliosarcoma** The following diagnosis subtypes allow : Choroid plexus papilloma Pineocytoma Lowgrade mixed glioma Primary CNS germ cell tumor Primary CNS lymphoma Solid leukemic lesion ( i.e. , chloromas , granulocytic sarcoma ) Pleomorphic xanthoastrocytoma , low grade Desmoplastic ganglioglioma Lowgrade astrocytoma Previously untreated disease Has undergone definitive surgery within past 42 day NOTE : *Patients receive treatment accord regimen D2 NOTE : **Patients receive treatment accord regimen C PATIENT CHARACTERISTICS : Bilirubin &lt; 1.5 mg/dL ALT AST &lt; 2.5 time upper limit normal Creatinine clearance and/or glomerular filtration rate ≥ 60 mL/min PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy chemotherapy Prior corticosteroid allow No concurrent corticosteroid antiemesis No concurrent brachytherapy electron radiotherapy No concurrent dairy product grapefruit juice temozolomide administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood pineoblastoma</keyword>
</DOC>